fbpx
Connect with us

BUSINESS

Kalytera Therapeutics Inc. (OTCMKTS:KALTF) Targeting $83 Billion Pain Management Market With KAL-1816

Published

on

Investor sentiments on Kalytera Therapeutics Inc. (OTCMKTS:KALTF) have edged higher on the confirmation that the company has made significant progress on the development of a new cannabinoid-based compound. KAL-1816 is the company’s first-in-class CBD molecule designated for the treatment of acute and chronic pain.

KAL-1816 Development

According to the company, KAL-1816 strongly binds and activates alpha3 glycine pain receptor, making it possible to shut down pain transmission in inflammatory conditions. According to CEO Robert Farrell, the new compound marks an important milestone in the company’s bid to come up with a cannabinoid analgesic for addressing pain in inflammatory conditions such as arthritis and sciatica.

Farrell expects KAL-1816 to provide effective pain relief without the risk of addiction, as is the case with opioids.

“The objective of our program has been to develop a potent, non-psychotropic, oral analgesic for the treatment of pain that will be safe and well tolerated. We believe that KAL-1816 has the potential to achieve these goals, and to become a next-generation pain medication,” said Mr. Farrell.

Plans are underway to advance Kal-1816 into series of IND studies including vivo efficacy studies as well as safety and pharmacokinetic studies. Kalytera Therapeutics has also filed a provisional patent to protect the composition of the compound.

Pain Relief Market Opportunity

KAL-1816 presents a big market opportunity in the treatment of pain in various medical conditions upon successful clinical trials. Kalytera is developing the product as a novel treatment for severe and chronic pain without the risk of respiratory suppression and dependence.

The global pain management market is on course to hit highs of $83 billion by 2024. The fact that people and d governments are increasingly shunning opioids presents a unique market opportunity for Kalytera Therapeutics. The company is also seeking to become a leading developer of novel cannabis medicines for unmet medical needs.

Continue Reading
Advertisement

BUSINESS

Cannabis Control Commission Approves ARL Healthcare, A Subsidiary Of Marimed Inc (OTCMKTS:MRMD), To Begin Cannabis Operations In Bedford

Published

on

Cannabis Control Commission (CCC) in Massachusetts gave its nod to ARL Healthcare Inc., a subsidiary of Marimed Inc (OTCMKTS:MRMD), to begin operations at Middleborough based Dispensary and production and cultivation facility in New Bedford. The company has hired the staff and would begin the operations at a Dispensary in Middleborough, and Bedford under the trademark ‘Panacea Wellness’ in the coming weeks.

Introduces Betties Eddies, and Kalm Fusion

Chief Operating Officer of Marimed, Tim Shaw said the company is pleased to receive approval to inaugurate cannabis operations. Armed with this approval, the company will unveil genetics and strains under the brand ‘Nature’s Heritage’ in the emerging markets like in Massachusetts. Marimed would launch Kalm Fusion, Betties Eddies, and the licensed brands: Tropizen, Tikun Olam, Binske, and The Healer in the Massachusetts markets.

Enrolls 60,000 patients in the medical program

Marimed enrolled more than 60,000 patients in the state medical program. In Massachusetts,  recreational sales are estimated at $500 million in 2019. According to Brightfield Group project analysts, the annual sales of recreational cannabis would touch over $2 billion by 2023. The demand for medicinal cannabis would reach $125 million by the year 2023.

Bob Fireman, Chief Executive Officer of Marimed, said its panacea wellness dispensary in Middleborough will improve the retail experience of cannabis patients supported by digital libraries and educational programs. Digital tablets facilitate ordering faster and improve sales. He further said the company will introduce its family of products across the state and cannabis patients will enjoy great products.

Highlights of Q3, 2019

Marimed has posted an increase of 231% in revenues in Q3 2019. The company derived revenues of $11.22 million from licensing fees, and management fees, and real-estate income. It has signed a licensing accord with Binske Brands for seven states. The company has appointed Jonathan Rider as the CIO. Marimed has also roped in Philip Frankenberg as President to head Hemp Product division. The major retailers would embrace the HempEngine CBD Product platform.

Marimed completed the takeover of Illinois based cannabis facilities. The company would include revenues generated from Massachusetts and Illinois in Q4 2019 results.

Continue Reading

BUSINESS

Choom Holdings Inc (OTCMKTS:CHOOF) Receives A Permit To A Retail Location In Kitsilano, Canada: Applies For A License To Open Cannabis Store in British Colombia

Published

on

Choom Holdings Inc (OTCMKTS:CHOOF) has received a developmental license to open a retail location in Kitsilano, Vancouver. President of Choom, Corey Gillon, said the company is excited to bring the experience of Choom Cannabis to Kitsilano, which supports cannabis culture.

Applies for recreational cannabis store license

Choom needs the approval of the Board of Variance from Vancouver City to operate a retail cannabis store that sells recreational cannabis. The company also applied for a license to inaugurate recreational cannabis store in British Columbia’s Liquor and Cannabis Regulation Branch.

Health Canada awards production licenses

Choom holds a stake of 9.8% in Sitka Weedworks. Health Canada has awarded two processing and production licenses to Sitka Weedworks. Armed with these licenses, Sitka would engage in the sale and manufacture of cannabis products that include edibles, capsules, vaporizer pens, pre-rolls, and dried flower. Sitka produces 2,200 plants. It plans to lease more cultivation spaces to fifty-three cannabis micro cultivators. The company would deliver craft cannabis to the legalized cannabis market in Canada.

Gets a development license in Vancouver BC

Choom has received a development license for a retail location in Vancouver, BC at 191 W.2nd Ave. Corey said the company is excited about securing a location for the flagship store in Vancouver City.

It gives an opportunity for the company to start a retail store in the Olympic City, which is now transformed into a dynamic and vibrant community. Choom is pleased to offer the topnotch retail experience to the visitors and residents of this vibrant community.

Choom has opened stores in Brooks, Drumheller, and Westlock in September 2019. The company already secured 78 leases of retail locations. It has completed six locations and progressing with the construction of ten stores. Choom already lodged 50 applications for the stores.

Appoints new CEO

Choom has announced the appointment of Corey Gillon as Chief Executive Officer. He will take charge as CEO on December 1, 2019. The appointment is subject to the approval of regulators. The current Chief Executive Officer – Chris Bogart will take the role of President from December 1, 2019. It is part of the company’s strategy to become a major cannabis retailer nationwide.

Continue Reading

BUSINESS

WeedMD Inc (OTCMKTS:WDDMF) Completes Harvest Of Outdoor Crop At Strathroy Facility: WeedMD Receives A License To Sell Cannabis Products

Published

on

WeedMD Inc (OTCMKTS:WDDMF) harvested cannabis outdoor crop on 27 acres at Strathroy facility, Ontario. It has to undergo processing and curing to eliminate harsh compounds and excessive moisture while retaining cannabinoids and terpenes. The company plans to harvest premium quality cannabis on 200 acres next year.

Enters commercial extraction operations

WeedMD has commenced the commercial extraction operation at the Aylmer facility. Health Canada awarded a license to allow WeedMD to manufacture and market topicals, edibles, and cannabis concentrates.

Chief Executive Officer of WeedMD, Keith Merker, said the company achieved a milestone by completing the outdoor harvest. Sitting with large amounts of cannabis, WeedMD sells the dried and other forms of cannabis in value-added formats in the coming days and quarters. It will emerge as a leader in the sale and production of cannabis extracts under economical production of the dried flower, and extraction business at the Aylmer facility.

CX Industries, a wholly-owned subsidiary of WeedMD, is capable to process 26,000 kgs of biomass every year with the recently commissioned extractor. The company will install the second Q-90 extractor rated for high throughput efficiency of CO2 in December 2019. It will install another two extractors next year. The annual extraction capacity at CX Industries would be 200,000 kgs of biomass. CX Industries and WeedMD would introduce innovative cannabis 2.0 products in January 2020 for Canadian customers.

Data-driven efficiency and transparency

WeedMD is added to the subscriber base of Strainprint Technologies. The company operates a 158-acre outdoor and greenhouse facility situated in Ontario. The annual production capacity of the greenhouse of WeedMD is over 20,000 kgs. The company also harvests an additional 20,000 kg of biomass at its Strathroy based outdoor cultivation platform that is based on 27 acres.

Senior Vice President (Marketing and Sales) of WeedMD, the main aim of working with Strainpoint is to ensure data-driven efficiency and transparency in the cannabis industry. It leverages the technology of Strainprint to bring high-quality cannabis products to the market.

WeedMD would announce Q3 results on November 28, 2019. CEO would host a conference call to discuss earnings at 10 AM on the same day.

Continue Reading



Trending Stories